by admin | Jul 21, 2023 | Press Releases
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated Promising preliminary efficacy signals with 33% disease...
by admin | Nov 9, 2022 | Press Releases
Friday, November 4, 2022 7:00 AM ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company...
by admin | May 25, 2022 | Press Releases
Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB...
by admin | Feb 8, 2021 | Press Releases
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE /...
by admin | Feb 4, 2019 | Press Releases
New York, NY., February 4th, 2019 — ENB Therapeutics, Inc., a clinical-stage, biopharmaceutical company developing innovative, endothelin-based oncologics, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD...
by admin | Sep 21, 2018 | Press Releases
New York, NY, September 20, 2018: ENB Therapeutics Inc., a biopharmaceutical company pioneering pathways in endothelin-based oncologics, today announced that it has closed its Series A private equity financing. Proceeds from the financing will be used to advance the...
